Get the Stockscreener App
1.87
3.89%
0.07
Alzamend Neuro Inc stock is traded at $1.87, with a volume of 28,204.
It is up +3.89% in the last 24 hours and down -11.79% over the past month.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
See More
Previous Close:
$1.80
Open:
$1.81
24h Volume:
28,204
Relative Volume:
0.31
Market Cap:
$7.11M
Revenue:
-
Net Income/Loss:
$-7.04M
P/E Ratio:
-0.4271
EPS:
-4.3784
Net Cash Flow:
$-6.17M
1W Performance:
-2.60%
1M Performance:
-11.79%
6M Performance:
-20.76%
1Y Performance:
-79.43%
1-Day Range:
$1.80
$1.89
1-Week Range:
$1.71
$1.96
52-Week Range:
$1.58
$9.90
Alzamend Neuro Inc Stock (ALZN) Company Profile
Name
Alzamend Neuro Inc
Sector
Industry
Phone
844-722-6333
Address
480 PEACHTREE ROAD NE, SECOND FLOOR, ATLANTA
Compare ALZN vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALZN
Alzamend Neuro Inc
|
1.87 | 6.85M | 0 | -7.04M | -6.17M | -4.3784 |
VRTX
Vertex Pharmaceuticals Inc
|
458.50 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.96 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
700.25 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
326.81 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
148.29 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-21 | Initiated | Ascendiant Capital Markets | Buy |
Alzamend Neuro Inc Stock (ALZN) Latest News
Alzamend Neuro, Inc. Receives Nasdaq Delisting Notice: SEC Form 8-K Filing March 2026 - Minichart
Alzamend Neuro Receives Nasdaq Notice Over Equity Deficiency - TipRanks
Alzamend Neuro Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
[8-K] Alzamend Neuro, Inc. Reports Material Event | ALZN SEC FilingForm 8-K - Stock Titan
Exit Recap: How sensitive is Alzamend Neuro Inc to inflationEarnings Performance Report & Free Verified High Yield Trade Plans - baoquankhu1.vn
Quarterly Recap: Will PAVM outperform during market rallies2026 Price Momentum & Short-Term High Return Strategies - baoquankhu1.vn
Alzamend initiates phase II trial of AL001 in bipolar disorder By Investing.com - Investing.com South Africa
Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital - Investing News Network
Alzamend Neuro initiates phase II clinical trial of AL001 "lithium in brain" study in patients with bipolar disorder in collaboration with Massachusetts General Hospital - marketscreener.com
Alzamend initiates phase II trial of AL001 in bipolar disorder - Investing.com
Alzamend Neuro Initiates Phase Ii Clinical Trial Of Al001 "Lithium In Brain" Study In Patients With Bipolar Disorder In Collaboration With Massachusetts General Hospital - TradingView
New bipolar trial scans how lithium reaches the brain at Mass General - Stock Titan
Alzamend Neuro, Inc. Q3 2026 Financial Results and SEC 10-Q Filing Overview - Minichart
Alzamend Neuro 10-Q: $0.00M Revenue, $(0.58) EPS Q3; $(1.89) EPS YTD - TradingView
Alzamend Neuro (NASDAQ: ALZN) posts $5.9M loss and warns on going concern - Stock Titan
Alzamend Neuro Establishes ATM Equity Offering Agreement - The Globe and Mail
Is Alzamend Neuro Inc stock a hidden gemEarnings Growth Report & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Alzamend Neuro Inc enters ATM sales agreement to sell up to $3.0 million in common stockSEC filing - marketscreener.com
Alzamend Neuro Launches $3 Million ATM Equity Program With Ascendiant Capital Markets - TradingView
Alzamend Neuro (ALZN) launches $3.0M at-the-market common stock offering - Stock Titan
Alzamend Neuro Inc expected to post a loss of $1.92 a shareEarnings Preview - TradingView
10 Health Care Stocks Moving In Monday's Pre-Market Session - Sahm
ALZN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ALZN Should I Buy - Intellectia AI
Alzamend Neuro (ALZN) to Release Quarterly Earnings on Monday - Defense World
Short Interest in Alzamend Neuro, Inc. (NASDAQ:ALZN) Expands By 51.2% - Defense World
ALZN Technical Analysis & ETF Price Forecast - Intellectia AI
Reverse split and new equity plan in Alzamend Neuro (ALZN) 2026 proxy - Stock Titan
How risky is Alzamend Neuro Inc. stock now2025 Key Lessons & Stepwise Entry/Exit Trade Alerts - mfd.ru
Can Alzamend Neuro Inc. stock hit record highs againMarket Activity Report & Verified Trade Idea Suggestions - mfd.ru
Is Alzamend Neuro Inc. benefiting from interest rate changesEarnings Overview Report & Daily Price Action Insights - mfd.ru
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Will Alzamend Neuro Inc. announce a stock splitJuly 2025 Chart Watch & Fast Momentum Entry Tips - mfd.ru
What’s the fair value of Alzamend Neuro Inc. stockQuarterly Earnings Summary & Reliable Entry Point Trade Alerts - mfd.ru
Alzamend Neuro (NASDAQ:ALZN) Stock Price Down 0.5% – Here’s Why - Defense World
Earnings Update: What is Alzamend Neuro Incs TAM Total Addressable MarketJuly 2025 Earnings & Technical Pattern Recognition Alerts - baoquankhu1.vn
EPS Watch: What is Alzamend Neuro Incs TAM Total Addressable MarketJuly 2025 Review & Fast Gain Stock Trading Tips - baoquankhu1.vn
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Is Community Health Systems Incs ROE strong enough2025 Biggest Moves & Real-Time Market Sentiment Reports - baoquankhu1.vn
Is Alzamend Neuro Inc. stock heavily shortedWeekly Profit Analysis & Daily Profit Maximizing Tips - bollywoodhelpline.com
Aug Sectors: Is Alzamend Neuro Inc stock heavily shortedJuly 2025 News Drivers & Weekly High Return Opportunities - baoquankhu1.vn
Bond Watch: Can Alzamend Neuro Inc stock beat market expectations this quarterQuarterly Growth Report & Capital Protection Trade Alerts - Bộ Nội Vụ
Alzamend Neuro (NASDAQ:ALZN) Stock Price Down 2.5% – Should You Sell? - Defense World
Can Alzamend Neuro Inc. stock beat analyst upgradesJuly 2025 Outlook & Safe Entry Point Identification - ulpravda.ru
ContactThe Lethbridge HeraldNews and Sports from around Lethbridge - FinancialContent
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Will Alzamend Neuro Inc. stock attract ESG investorsJuly 2025 Outlook & Precise Swing Trade Entry Alerts - Улправда
Will Alzamend Neuro Inc. stock return to pre crisis levelsJuly 2025 Short Interest & Safe Entry Zone Tips - ulpravda.ru
What technical charts say about Alzamend Neuro Inc. stockQuarterly Performance Summary & Reliable Price Breakout Alerts - ulpravda.ru
Is AIM ImmunoTech (AIM) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Alzamend Neuro, Inc.Common Stock (NQ: ALZN - FinancialContent
Alzamend Neuro Inc Stock (ALZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alzamend Neuro Inc Stock (ALZN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Horne William B. | Director |
Dec 19 '25 |
Sale |
2.12 |
3,333 |
7,059 |
0 |
| McGrath Lynne Fahey | Director |
Oct 23 '25 |
Sale |
2.29 |
30 |
69 |
25 |
| AULT MILTON C III | Director |
Oct 08 '25 |
Sale |
2.44 |
101,394 |
247,158 |
28,657 |
| AULT MILTON C III | Director |
Oct 09 '25 |
Sale |
2.32 |
20,397 |
47,390 |
8,260 |
| AULT MILTON C III | Director |
Oct 06 '25 |
Sale |
2.45 |
82,033 |
201,268 |
26,227 |
| AULT MILTON C III | Director |
Oct 07 '25 |
Sale |
2.49 |
57,379 |
142,954 |
68,848 |
| AULT MILTON C III | Director |
Oct 03 '25 |
Sale |
2.44 |
65,903 |
160,889 |
8,260 |
| AULT MILTON C III | Director |
Oct 01 '25 |
Sale |
2.35 |
36,777 |
86,378 |
94,849 |
| AULT MILTON C III | Director |
Oct 02 '25 |
Sale |
2.39 |
20,686 |
49,522 |
74,163 |
| AULT MILTON C III | Director |
Sep 29 '25 |
Sale |
2.31 |
38,324 |
88,490 |
35,192 |
2.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):